NNVC: NanoViricides, Inc. Stock

by  •  • Comments Off on NNVC: NanoViricides, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 14.13
Enterprise Value ($M) 8.89
Book Value ($M) 12.45
Book Value / Share 1.06
Price / Book 1.14
NCAV ($M) 4.37
NCAV / Share 0.37
Price / NCAV 3.24

Profitability (mra)
Return on Invested Capital (ROIC) -0.75
Return on Assets (ROA) -0.50
Return on Equity (ROE) -0.51

Liquidity (mrq)
Quick Ratio 5.59
Current Ratio 5.59

Balance Sheet (mrq) ($M)
Current Assets 5.32
Assets 13.40
Liabilities 0.95
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2023 Commission File Number: 001-36081
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 Commission File Number: 001-36081
2023-10-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2023 Commission File Number 001-36081 NANOVIRI
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 Commission File Number: 001-36081 NAN

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-01 826 7,750 10.66
2024-04-30 10,835 41,418 26.16
2024-04-29 10,832 25,551 42.39
2024-04-26 135 5,699 2.37

(click for more detail)

Similar Companies
MAIA – MAIA Biotechnology, Inc. MTNB – Matinas BioPharma Holdings, Inc.
NBY – NovaBay Pharmaceuticals, Inc. OGEN – Oragenics, Inc.
PHGE – BiomX Inc.


Financial data and stock pages provided by
Fintel.io